Idexx Laboratories, Inc.

Other

Idexx Corporation

Restalyst Pte Ltd

Robert L Lawton

Eugene Regis Krah, Iii

Thomas Patrick O'Connor, Jr

Paul Scott MacHenry

Brion Mermer

Hongliang Guo

Barbara Ann Bartol

Ashok P Aiyappa

Eustache Paramithiotis

Lisa Ann Estey

Marc Pinard

Neil Cashman

Sylvie La Boissière

Susan Francoeur, Legal Representative

Greg Francoeur

Wendy W Liu

The present invention relates to a method of detection of a compound of interest that is present at low levels in a sample. In particular, the present invention relates to a method of detection of a compound of interest in solution by a nucleic acid-labelled binding construct, separation of the unbound nucleic acid-labelled binding construct, and the detection of the bound nucleic acid-labelled binding construct in the solution phase. The present invention is particularly adaptable to be used in conjunction with a nucleic acid amplification reaction for detecting the presence or absence of the nucleic acid portion of binding construct in a sample indicating the presence or absence of the compound of interest.

Soluble analyte detection and amplification

The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.

Methods and compositions for inhibiting binding of IgE to a high affinity receptor

The invention provides methods and compositions for the detection ofandantibodies and antibody fragments.

[object Object]

The present invention features methods for identifying peptides that selectively bind to PrPor fragments thereof. The invention also features the use of such peptides in screening methods for the identification of candidate agents useful for the treatment of a prion disease.

The present invention provides canine heavy chain and light chain (both &#x3bb; and &#x3ba;) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised of the presently disclosed canine variable domain framework sequences and CDRs specific for an antigen obtained from antibodies from other than canines (preferably mouse). The invention also provides methods of making caninized antibodies and using them. This disclosure specifically describes caninized antibodies that are useful in the treatment of canine allergy. The general process of caninization permits the development of useful therapeutics, which includes but is not limited to allergy, osteosarcomma's and lymphomma's.

Methods for using canine immunoglobulin variable domains and caninized antibodies

Disclosed are binding proteins that specifically bind to an isolated and purified peptide comprising a leucine positioned two peptide bonds away from a tyrosine-arginine pair. Other binding proteins of the invention include those that specifically bind to an isolated and purified peptide with the sequence cysteine-blank-blank-proline-histidine-blank-blank-blank-cysteine (SEQ ID NO:6) or cysteine-blank-proline-histidine-blank-proline-blank-blank-cysteine (SEQ ID NO:9).

Specific binding proteins for treating canine allergy

The present invention provides the nucleotide and amino acid sequences of canine IL-5. It also sets forth a recombinant DNA molecule, and conservative variants thereof, comprising the DNA sequence of canine IL-5, and recombinant vectors such as expression vectors, comprising a DNA sequence encoding canine IL-5. Further, the invention sets forth polypeptides produced using a recombinant expression vector containing a canine IL-5 sequence. Also disclosed are compositions comprising a nucleotide sequence that is antisense to a DNA sequence encoding a component of canine IL-5, wherein the component can be the full canine IL-5 protein. Disclosed are a cloning vector comprising a DNA sequence of canine IL-5 cDNA material; a recombinant cell line comprising a DNA sequence of the canine IL-5 cDNA material; a method for producing a polypeptide comprising a step of expressing a peptide comprising an amino acid sequence encoded by a cloning vector comprising canine IL-5 cDNA material; and a cell that expresses a recombinant polypeptide encoded by a DNA sequence (or conservative variants thereof) that encodes canine IL-5 or components thereof. Furthermore, antibodies that bind to canine IL-5, and mimetopes of IL-5 epitopes are also disclosed.

Methods and compositions concerning canine interleukin 5

The present invention provides methods and compositions for decreasing IgE levels in dogs. The methods and compositions are useful for treating allergic symptoms in dogs. The invention may comprise chimeric canine anti-IgE monoclonal antibody compositions and methods for using the compositions in the treatment of allergy. In preferred embodiments, the compositions of the present invention may act by binding soluble IgE in plasma, or by inhibiting IgE from binding to receptors on mast cells, B cells, and basophils.

Growing community of inventors

Gorham, ME, United States of America

Robert L Lawton